A Phase I Dose-Escalation Study of Fractionated Stereotactic Radiosurgery in Combination With Gefitinib in Patients With Recurrent Malignant Gliomas

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 4, 2008, Pages 993-1001

  Schwer, Amanda L ^a   Damek, Denise M ^a   Kavanagh, Brian D ^a   Gaspar, Laurie E ^a   Lillehei, Kevin ^a   Stuhr, Kelly ^a   Chen, Changhu ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

gefitinib; Iressa; recurrent malignant gliomas; SRS; Stereotactic radiosurgery

Indexed keywords

MEDICAL PROBLEMS; SURGERY; TUMORS;

IRESSA; RECURRENT MALIGNANT GLIOMAS; STEREOTACTIC RADIOSURGERY;

ONCOLOGY;

CARMUSTINE; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; DOSE FRACTIONATION; FEMALE; GLIOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; QUINAZOLINES; RADIOSURGERY; TREATMENT OUTCOME;

EID: 39749192759     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.07.2382     Document Type: Article

References (31)

1. Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359 (2002) 1011-1018
2. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J Clin Oncol 17 (1999) 2572-2579
3. Hess C.F., Schaaf J.C., Kortmann R.D., et al. Malignant glioma: Patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30 (1994) 146-149
4. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-brain tumor treatment group. Lancet 345 (1995) 1008-1012
5. Schrieve D.C., Alexander E., Wen P.Y., et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36 (1995) 275-282
6. Cho K.H., Hall W.A., Gerbi B.J., et al. Single dose versus fractionated stereotactic radiosurgery for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45 (1999) 1133-1141
7. Hudes R.S., Corn B.W., Werner-Wasik M., et al. A Phase I dose escalation study of hypofractionated stereotactic radiosurgery as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43 (1999) 293-298
8. Shepherd S.F., Laing R.W., Cosgrove V.P., et al. Hypofractionated stereotactic radiosurgery in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37 (1997) 393-398
9. Glass J., Silverman C.L., Axelrod R., et al. Fractionated stereotactic radiosurgery with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol 20 (1997) 226-229
10. Lederman G., Wronski M., Arbit E., et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Amer J Clin Oncol 23 (2000) 155-159
11. Laing R.W., Warrington A.P., Graham J., et al. Efficacy and toxicity of fractionated stereotactic radiosurgery in the treatment of recurrent gliomas (Phase I/II study). Radiother Oncol 27 (1993) 22-29
12. Vordermark D., Kolbl O., Ruprecht K., et al. Hypofractionated stereotactic re-irradiation: Treatment option in recurrent malignant glioma. BMC Cancer 5 (2005) 55
13. Wurm R.E., Kuczer D.A., Schlenger L., et al. Hypofractionated stereotactic radiosurgery combined with topotecan in recurrent malignant glioma. Int J Radiat Oncol Biol Phys 66 Suppl. 4 (2006) S26-S32
14. Liebermann T., Nussbaum H., Razon N., et al. Amplification, enhanced expression and possible rearrangement of EGF-receptor gene in primary human tumors of glial origin. Nature 313 (1985) 144-147
15. Ekstrand A.J., Longo N., Hamid M.L., et al. Functional characterization of a EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGF-R gene amplification. Oncogene 9 (1994) 2313-2320
16. Naruse I., Ohmori T., Ao Y., et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (GEFITINIB) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98 (2002) 310-315
17. Anderson N.G., Ahmad T., Chan K., et al. Gefinitib (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94 (2001) 774-782
18. Heimberger A.B., Learn C.A., Archer G.E., et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res 8 (2002) 3496-3502
19. Bianco C., Tortora G., Bianco R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8 (2002) 3250-3258
20. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
21. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
22. Shaw E., Kline R., Gillin M., et al. Radiation Therapy Oncology Group: Radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys 27 (1993) 1231-1239
23. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed April 20, 2007.
24. Brown P.D., Buckner J.C., O'Fallon J.R., et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein Mini-Mental State Examination. J Clin Oncol 21 (2003) 2519-2524
25. Brown P.D., Jensen A.W., Felten S.J., et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol 24 (2006) 5427-5433
26. Guerrero M., and Li X.A. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49 (2004) 4825-4835
27. Shaw E., Scott C., Souhami L., et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47 (2000) 291-298
28. Van der Kogel A.J. Radiation response and tolerance of normal tissues. In: Steel G.G. (Ed). Basic clinical radiobiology. 2nd ed. (1997), Arnold, London 30-39
29. Mullins M.E., Barest G.D., Schaefer P.W., et al. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. Am J Neuroradiol 26 (2005) 1967-1972
30. Rabinov J.D., Lee P.L., Barker F.G., et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: Initial experience. Radiology 225 (2002) 871-879
31. McGirt M.J., Bulsara K.R., Cummings T.J., et al. Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. J Neurosurg 98 (2003) 14-20